Navigation Links
A promising new approach to cadmium induced hepatoxicity: Cytoprotective effect of midkine
Date:1/16/2008

Cadmium comes from a wide variety of sources in the environment and from industry and is extremely toxic to humans. Environmental exposure can occur via the diet and drinking water. In chronic exposure, it also accumulates in the body, particularly in the kidneys and the liver. The liver acts as a detoxification organ. It filters the blood coming from the gastrointestinal tract and liver cells can be exposed to almost whole ingested and absorbed molecules and toxins at their highest concentrations through the portal vein. At present, there is no effective treatment for cadmium intoxication other than symptomatic treatment. Some chelating compounds are used for this purpose.

A research article published on January 7, 2008 in the World Journal of Gastroenterology (volume 14, issue 1) addresses this problem. An understanding of the processes that ensure self-protection against toxic substances is essential for the development and application of new therapeutic regimens. In research conducted in hepatocyte cell culture, cadmium exposure causes dose and time dependent damage in liver cells. Dr. Yazihan et al found cadmium intoxication stimulates secretion of midkine in a dose and time dependent manner. Midkine is mitogenic to cells. Midkine expression is found in the liver from early gestation. It is a heparin binding growth factor that regulates cell growth, survival, and differentiation. In this study it was found that exogenous midkine application induces hepatocyte proliferation. Midkine treatment prevented apoptosis, lactate dehydrogenase leakage and cytotoxicity caused by cadmium exposure in Hep3B cells. Midkine secretion might be one of the self defense mechanisms of the hepatocytes. The results of this study suggest a promising future therapy with midkine in cadmium induced hepatotoxicity. Midkine may also be beneficial to other hepatotoxic conditions.


'/>"/>

Contact: Jing Zhu
wjg@wjgnet.com
86-105-908-0039
World Journal of Gastroenterology
Source:Eurekalert

Page: 1

Related medicine news :

1. Malaria Drug Promising Against Cancer
2. Results promising for computational quantum chemical methods for drug development
3. An international first at the CHUM - Promising treatment in regeneration of the myocardium through the use of stem cells
4. Highly Promising Dutch Research Into Alzheimers Disease and Parkinsons Disease
5. Drug study for brain cancer shows promising results
6. Naviscans PEM Flex(TM) Scanner Shows Promising New Data in Breast Cancer Management
7. 3-drug combination extremely promising as first-line therapy for multiple myeloma
8. OPKOs Bevasiranib Named One of Most Promising Drugs Recently Entering Phase III Trials
9. UCSF launches action tank to advance promising global health strategies
10. Protalix BioTherapeutics prGCD Named One of the Five Most Promising Drugs Entering Phase III Trials by Thomson Scientific
11. Thomson Scientific Publishes its Third Quarter Issue of the Ones to Watch Reviewing the Most Promising Drugs in the Pharmaceutical Pipeline
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... ... December 08, 2016 , ... The ... the Undersea and Hyperbaric Medical Society (UHMS), the leading authority in hyperbaric medicine. ... safety. Only a few hospitals and facilities have earned this distinction. This is ...
(Date:12/8/2016)... ... December 08, 2016 , ... Russ ... announced the first national #QuackGivesBack campaign which supported local breast cancer organizations during ... franchise-wide Quack Gives Back initiative, and we’re very pleased with the ...
(Date:12/8/2016)... Pa. (PRWEB) , ... December 08, 2016 , ... ... Medicine Southern Chester County, a Property owned by an affiliate of Seavest, has ... square foot Penn Medicine Southern Chester County ambulatory care center (ACC) was named ...
(Date:12/8/2016)... (PRWEB) , ... December 08, 2016 , ... CURE Media ... centers and advocacy groups, has aligned with Upstage Lung Cancer in efforts to combat ... the announcement, Michael J. Hennessy, Jr said, “CURE Media Group is honored to team ...
(Date:12/8/2016)... ... December 08, 2016 , ... David J. Dykeman , ... Greenberg Traurig, LLP, will speak at DeviceTalks West, Dec. 12, 2016, at the Fairmont ... and attorneys from the firm’s global Life Sciences & Medical Technology Group have been ...
Breaking Medicine News(10 mins):
(Date:12/9/2016)... OSAKA, Japan , Dec. 9, 2016 ... ; President & Representative Director, CEO: Dr. ... with amyotrophic lateral sclerosis (ALS) given edaravone intravenously in ... functional loss as measured by the ALS Functional Rating ... th International Symposium on ALS/MND in ...
(Date:12/9/2016)... 9, 2016  Axovant Sciences Ltd. (NYSE: ... focused on the treatment of dementia, today announced ... Phase 2b trial evaluating treatment with intepirdine (RVT-101), ... donepezil plus placebo in people with mild-to-moderate Alzheimer,s ... intepirdine to treatment was associated with reduced progression ...
(Date:12/8/2016)... 8, 2016 KEY FINDINGS ... Patient warming and ... blood during surgeries, lowering the risks of neurological disorders post ... SSIs. The patient warming systems can be segmented into convective ... in turn reduce the stay at hospitals thus, lowering the ...
Breaking Medicine Technology: